{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "KURA",
  "name": "Kura Oncology, Inc.",
  "url": "https://orbyd.app/dossiers/KURA/",
  "json_url": "https://orbyd.app/dossiers/KURA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A maturing special-situation biotech in a two-year catalyst gap; the ~2026-08-06 Q2 print is the next real read, not an accelerating setup.",
  "invalidation_trigger": "A weekly close below $9.50 breaks the post-approval consolidation base and loses the rising 200-day; confirmed if the ~2026-08-06 Q2 print shows KOMZIFTI revenue stalling near Q1's $5.8M, or the menin-inhibitor class flips to saturated as revumenib and bleximenib take frontline share.",
  "catalyst_date": "2026-08-06",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-08-03",
  "invalidation_fired": true,
  "themes": [
    "oncology-immunology",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Momentum trigger to upgrade: weekly close above the $12.49 52-week high on a launch/frontline inflection.",
    "Q2 2026 earnings est. ~2026-08-06 (Q2'25 was 2025-08-07; Q1'26 was 2026-05-12) — second full KOMZIFTI quarter; avoid fresh entries into the print, binary launch-trajectory read.",
    "True next transformational binary is KOMET-017 Phase 3 top-line ~2028 — long catalyst gap, size small.",
    "Commercial traction confirmed: ~40% of new R/R NPM1-m patient starts, payer access >93% of covered lives (EHA 2026 / Q1 update).",
    "Safety edge vs Syndax revumenib: ziftomenib has no QTc/Torsades boxed warning — the frontline chemo-combo differentiator.",
    "Funded through the 2028 readout: ~$580.8M cash at 2026-03-31 + ~$180M Kyowa payments — no near-term dilution catalyst.",
    "Darlifarnib (FTI) + cabozantinib in RCC is early Phase 1 optionality; 2026-07-27 investor call is a secondary-asset read that rarely re-rates the whole company.",
    "Momentum upgrade trigger: weekly close above the $12.49 52-week high on volume with a launch-inflection Q2 print."
  ],
  "body_markdown": "## Current Thesis\nThe re-rating already fired. Ziftomenib (KOMZIFTI) won FDA approval on 2025-11-13 for relapsed/refractory NPM1-mutant AML — the first once-daily oral menin inhibitor — and the stock ran from a $5.45 pre-approval low (2025-08-11) to a $12.49 post-approval high (2025-11-14). Eight-plus months on, the tight consolidation near that high has given way: KURA printed $10.39 on 2026-07-25, drifting into the lower third of the $10–12.5 range it held all of H1 2026. The trade the Street underwrites — frontline AML expansion behind the $24–28 price targets — is gated to a Phase 3 (KOMET-017) that does not read out until 2028. That is a de-risked, target-cheap biotech in a two-year catalyst gap with a slowly eroding tape, not an accelerating narrative a momentum book gets paid to chase. The near-term reads are a 2026-07-27 darlifarnib data call and the second full KOMZIFTI launch quarter, due early August.\n\n## Bull Case\n- KOMZIFTI captured ~40% of new patient starts in R/R NPM1-mutant AML with payer access secured for >93% of covered lives (EHA 2026 / Q1 update, 2026-06-14) — fast share capture in its approved niche.\n- Q1 2026 net product revenue $5.8M, the first full commercial quarter, up from a $2.1M launch stub (first sale 2025-11-21 through 2025-12-31) — the sequential ramp is real, not clinical-stage promise.\n- Frontline data is strong: KOMET-007 long-term results (2026-06-12) showed 96% CR in NPM1-m and 90% in KMT2A-r, 12-month overall survival 94% / 71%, high MRD-negativity, and a manageable safety profile — one of the larger menin-plus-chemo frontline datasets and the basis for KOMET-017.\n- Safety differentiation versus Syndax's revumenib (Revuforj): ziftomenib carries no QTc-prolongation/Torsades boxed warning, which matters as the class pushes into frontline chemo combinations.\n- Funded to the binary: ~$580.8M cash and investments at 2026-03-31 plus ~$180M anticipated Kyowa Kirin payments fund the ziftomenib program through the 2028 KOMET-017 top-line; the Kyowa deal (Nov 2024) runs up to $1.161B total with 50/50 US profit share, and a $30M KOMET-017 first-dosing milestone is already paid.\n- Second shot on goal: darlifarnib (farnesyl transferase inhibitor) plus cabozantinib in renal cell carcinoma — updated long-term FIT-001 Phase 1a/1b follow-up presented at KCRS 2026 (2026-07-24), with a virtual investor call 2026-07-27.\n- Sell-side well above spot: Citizens reiterated Market Outperform, $24 target (2026-06-15); consensus range roughly $16–76 against a $10.39 tape.\n\n## Bear Case\n- The catalyst that mattered is in the rearview. Approval fired 2025-11-13, and the stock now trades ~17% below its post-approval high and has ground lower through July ($11.44 on 2026-07-10 → $10.39 on 2026-07-25).\n- Two-year catalyst desert: the transformative KOMET-017 Phase 3 top-line is not expected until 2028, leaving no binary to force a re-rate and room to bleed.\n- Crowded class: Syndax's Revuforj reached market first (covers both KMT2A-r and R/R NPM1); J&J's bleximenib, Sumitomo's enzomenib and Servier's S243249 are advancing. Frontline share is contested, and Kura lost the initial R/R race.\n- The approved indication is a narrow R/R NPM1 monotherapy niche; the $24–28 targets require frontline standard-of-care adoption that has not been demonstrated commercially.\n- Burn is real: cash fell ~$86M in Q1 ($667.2M at 2025-12-31 → $580.8M at 2026-03-31); runway leans on Kyowa milestones landing on schedule.\n- Darlifarnib is early Phase 1 — optionality only; a secondary-asset data call rarely re-rates a whole company on its own.\n\n## Setup & Price Structure\n- $10.39 (2026-07-25). 52-week range $5.45 (2025-08-11) to $12.49 (2025-11-14, post-approval).\n- The H1 2026 range was roughly $10–12.5; price now sits in the lower third and has stepped down through a series of lower highs since the November spike — the post-approval base is softening rather than coiling for a breakout.\n- ~$9.50 is the line that matters: a weekly close beneath it breaks the consolidation base and loses the rising 200-day.\n- No parabola, no volume expansion, RSI mid-range — dormant, drifting tape and the opposite of a momentum entry. A reclaim of the $12.49 high on expanding volume is the only tell that a fresh leg is starting.\n\n## Catalyst Calendar (next 30 days)\n\n- No FDA/PDUFA date or Phase 3 readout in the window; the next transformational binary (KOMET-017) is ~2028.\n\n## Elapsed catalysts\n\n- 2026-07-27 — virtual investor call on darlifarnib FIT-001 Phase 1a/1b long-term data (post-KCRS 2026, data shown 2026-07-24). Secondary-asset read with modest move potential. *(passed 13d ago)*\n- ~2026-08-06 (est.) — Q2 2026 financial results, the second full KOMZIFTI launch quarter (Q2 2025 landed 2025-08-07; Q1 2026 on 2026-05-12). The key near-term binary: sequential revenue over $5.8M and durability of the >40% share and payer access. Avoid fresh entries into the print. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- Upside re-rate: a weekly close above $12.49 on expanding volume, ideally alongside a Q2 print showing clear sequential acceleration over $5.8M and durable >40% share — that flips the read from dormant to a launch-inflection setup worth chasing.\n- Downside confirmation: a weekly close below $9.50 breaking the base and losing the rising 200-day; or a Q2 KOMZIFTI print stalling near Q1's $5.8M; or the menin-inhibitor class flipping to saturated as revumenib and bleximenib take frontline share.\n- Frontline optionality: positive KOMET-017 enrollment or interim signals, or an accelerated regulatory path, could compress the 2028 catalyst gap and warrant fresh interest ahead of the print.\n\n## Correlation Notes\n- Menin-inhibitor / AML complex: trades with Syndax (SNDX, revumenib) as the direct comp; class sentiment swings on frontline data from J&J (bleximenib), Sumitomo (enzomenib) and Servier (S243249).\n- Partner read-through: Kyowa Kirin milestone flow and commentary drive the US profit-share narrative and the 2028 runway math.\n- Small-cap biotech beta: sensitive to XBI/IBB risk appetite and rate moves; a two-year catalyst gap makes it a low-catalyst, funding-cost-sensitive name that tends to drift with the group rather than lead it.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T12:26:05+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}